HOD08: Reduced Duration Stanford V Chemotherapy With or Without Low-Dose Tailored-Field Radiation Therapy for Favorable Risk Pediatric Hodgkin Lymphoma


Leukemias / Lymphomas : Hodgkin lymphoma


This is a research study for participants that have a type of cancer called Hodgkin Lymphoma (cancer of the lymph system). Hodgkin lymphoma is one of the most treatable and curable childhood cancers. The standard treatment involves chemotherapy and radiation therapy. Although most patients get cured from their cancer, some experience bad side effects from treatment later in life, often referred to as “late effects”. It is thought that if some patients can be successfully treated with less intense therapy, these patients might have less “late effects”.

In this study, participants whose disease completely goes away after treatment with 8 weeks of chemotherapy will be finished with treatment. They will not receive radiation therapy. The anti-cancer drug combination that they receive is a reduced duration (8 weeks instead of 12) of Stanford V which is a multi-agent dose-intense chemotherapy with low cumulative doses of the individual chemotherapy agents. Participants whose disease doesn’t go away after the initial treatment with 8 weeks of chemotherapy will receive radiation therapy to the cancer sites.



For the current eligibility status of this clinical study, referring physicians must contact St. Jude Children's Research Hospital at 1-866-2ST-JUDE (1-866-278-5833).

Contact Information

Dr. Monika Metzger, MD
St. Jude Children’s Research Hospital
262 Danny Thomas Place
Memphis, TN 38105 USA
Voice: 1-866-2ST-JUDE  (1-866-278-5833)
FAX: 901-595-5068

Referring or consulting physicians only:

For all other inquiries about St. Jude Children's Research Hospital studies:


The above information is intended to provide only a basic description about a research protocol that may be currently active at St. Jude. The details made available here may not be the most up-to-date information on protocols used by St. Jude. To receive full details about a protocol and its status and or use at St. Jude, a physician must contact St. Jude directly.